Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05482321
Other study ID # 19-1543
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 27, 2023
Est. completion date September 2024

Study information

Verified date November 2023
Source University of Colorado, Denver
Contact Morgan Sooy
Phone 303 724 7526
Email morgan.sooy@cuanschutz.edu
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the pancreas of human subjects. The investigators will then determine 1) whether these pancreas blood flow factors differ between healthy subjects and those who have recently developed type1 diabetes; and 2) how variable measurements are in healthy subjects and subjects that recently developed type1 diabetes, both between subjects and over time. To address these aims the investigators will perform pancreas ultrasound measurements in each subject using an approved injectable 'bubble' contrast agent that allows measurement of pancreas blood flow. The investigators will compare ultrasound measurement with characteristics of the subject's type 1 diabetes, including genetic factors, glucose levels and other circulating factors, as well as other factors that may influence blood flow in the pancreas independent of type1 diabetes. The successful conclusion of this study will indicate whether measuring pancreas blood flow speed/volume will be helpful in monitoring whether type1 diabetes will emerge and thus will allow a large scale study to answer this question.


Description:

Study Design and Research Methods Part I: 5 subjects from SOP group Goal: Optimize settings for destruction-replenishment contrast-enhanced ultrasound scan 1. Subject recruited at the Barbara Davis Center 2. Subject provides written consent 3. Review medical history (exclusion if required) 4. Subject refrains from eating for ~6h prior to measurement 5. Subject visits University of Colorado Hospital CTRC echo lab 6. CTRC staff places peripheral intravenous line (PIV) 7. Research staff collects vital signs, height and weight 8. Subject received conventional ultrasound scan to locate pancreas tail (by Sonographer, verified by radiologist). 9. Subject receives DEFINITY dose 10. Subject receives destruction-replenishment contrast-enhanced ultrasound scan (adjust settings to optimize) 11. Pause for 30 minutes, allowing subject to stand and move 12. Repeat steps 9-11 (once). 13. Subject de-identified. 14. Analyze data. Part II: 30 subjects from control group (healthy controls and multiple islet autoantibody positive subjects), 15 subjects from T1D group. Goal: characterize subject variability and test whether healthy subjects and those with T1D show differing contrast measures 1. Subject recruited at the Barbara Davis Center 2. Subject provides written consent 3. Review medical history (exclusion if required) 4. Subject refrains from eating for ~6h prior to study 5. Subject visits University of Colorado Hospital CTRC echo lab 6. Subject completes questionnaire (family history of diabetes, exclusion criteria) 7. CTRC staff places peripheral intravenous line (PIV) 8. Research staff collects vital signs, height and weight 9. Subject received conventional ultrasound scan to locate pancreas tail (by Sonographer, verified by radiologist). 10. Subject receives DEFINITY dose 11. Subject receives destruction-replenishment contrast-enhanced ultrasound scan (under SOP) 12. Pause for 30 minutes, allowing subject to stand and move 13. Repeat steps 10-12 (once). 14. Subject de-identified 15. Analyze data. In part I a single repeat measurement may be made to aide in the optimization of data collection. In part II a single repeat measurement is made to assess short-term intra-subject measurement variability. In part I and part II, a subject will be asked to return on a separate date (within 1 year of the initial scan) for a repeat procedure using an additional DEFINITY delivery method (bolus or infusion, whichever was not given at the initial visit) or if data collection was not of sufficient quality during the first visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male or non-pregnant female age 18-65 - Ability and willingness of patient to participate fully in all aspects of this clinical study - Written informed consent obtained and documented Exclusion Criteria: - Excessive body size preventing effective scan of the pancreas as determined by sonographer - Evidence of exocrine pancreatic disease, including pancreatitis, cystic fibrosis, pancreatic adenocarcinoma, or neuroendocrine tumor. - Subjects who are pregnant or breast-feeding - Subjects incapable of giving assent/informed written consent - Known or suspected hypersensitivity to perflutren - Known history or suspected unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)

Study Design


Intervention

Drug:
Definity Suspension for Injection
DEFINITY is administered as per manufactures instructions 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial. Deliver a dose of 10 µl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds. Following imaging, provide a 10 mL flush of preservative-free saline Wait at least 30minutes until second dose (if provided).

Locations

Country Name City State
United States University of Colorado Anschutz, Barbara Davis Center Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary outcome 1 Optimized a contrast-enhanced ultrasound 'destruction-replenishment' protocol for imaging pancreas blood flow kinetics in adult human subjects. End of part I (6 months)
Primary Primary outcome 2 Comparison of pancreas blood flow kinetics (i.e. 'destruction-replenishment' k2 'reperfusion rate' parameter) between control and T1D subjects. End of part II (1 year)
Primary Primary outcome 3 Determining inter-subject variability in pancreas blood flow kinetics (i.e. the 'destruction-replenishment' k2 'reperfusion rate' parameter) among control subjects and among T1D subjects End of part II (1 year)
Primary Primary outcome 4 Determining reproducibility in the measurement of pancreas blood flow kinetics (i.e. the 'destruction-replenishment' k2 'reperfusion rate' parameter) within subjects. This will initially focus on short-term intra-subject measurement variability. End of part II (1 year)
Secondary Secondary outcome 1 Comparison between control and T1D subjects for other parameters resulting from the measurement of pancreas blood flow kinetics (i.e. the 'destruction-replenishment' 'reperfusion amplitude' A, 'destruction efficiency' 1-B and 'pre-destruction signal' parameters). End of part II (1 year)
Secondary Secondary outcome 2 Determining inter-subject variability among control subjects and among T1D subjects for other parameters resulting from the measurement of pancreas blood flow kinetics (i.e. the 'destruction-replenishment' 'reperfusion amplitude' A, 'destruction efficiency' 1-B and 'pre-destruction signal' parameters). End of part II (1 year)
Secondary Secondary outcome 3 Correlation of pancreas blood flow kinetics with blood glucose and HbA1c (to test for a link between the measurement and glucose control). End of part II (1 year)
Secondary Secondary outcome 4 Comparison of pancreas blood flow kinetics with HLA haplotype or whether subject has first-degree relative with T1D (to test for a link between the measurement and T1D genetic risk). End of part II (1 year)
Secondary Secondary outcome 5 Comparison of pancreas blood flow kinetics with subject BMI, age, heart rate, blood pressure (to test for a link between the measurement and subject characteristics) End of part II (1 year)
Secondary Secondary outcome 6 Assessment of subject autoantibodies, c-peptide levels (to ensure subjects free of diabetes do not have islet autoimmunity and to ensure subjects with T1D have islet autoimmunity and residual beta cell mass) End of part II (1 year)
See also
  Status Clinical Trial Phase
Completed NCT03886974 - Transition to Adult Care in Type 1 Diabetes
Completed NCT05620251 - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Active, not recruiting NCT05078658 - Low-carbohydrate Diet in Children With Type 1 Diabetes N/A
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT03177096 - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes N/A
Not yet recruiting NCT06418269 - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes N/A
Completed NCT04172077 - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting NCT04950634 - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed NCT04450745 - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients N/A
Completed NCT03165786 - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes N/A
Terminated NCT04028960 - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase Phase 2
Recruiting NCT05324488 - Diabetes Registry Graz for Biomarker Research
Completed NCT02984709 - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes N/A
Completed NCT02984514 - Brown Adipose Tissue in Type 1 Diabetes N/A
Recruiting NCT06372392 - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps N/A
Recruiting NCT05973799 - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes N/A
Recruiting NCT03311516 - New Insulin Therapy by Multiwave Bolus N/A
Completed NCT03711656 - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques N/A